Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Neonc Technologies, Inc.
University of Pittsburgh
Maastricht University Medical Center
Emory University
Iovance Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris